Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 224Rectal Neoplasms 124Colonic Neoplasms 120Stomach Neoplasms 60Pancreatic Neoplasms 58Neoplasm Metastasis 48Lymphoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Leukemia 32Esophageal Neoplasms 32Neoplasms 31Burkitt Lymphoma 19Adenocarcinoma Of Esophagus 17Adenocarcinoma 17Carcinoma, Hepatocellular 13Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Unspecified Adult Solid Tumor, Protocol Specific 11Biliary Tract Neoplasms 11Lymphoma, Mantle-Cell 10Gallbladder Neoplasms 10Liver Neoplasms 9Osteosarcoma 8Lymphoma, Large-Cell, Immunoblastic 8Gastrointestinal Neoplasms 8Bile Duct Neoplasms 8Lymphoma, Follicular 7Dendritic Cell Sarcoma, Interdigitating 7Cholangiocarcinoma 7Leukemia, Myeloid, Acute 6

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Paresthesia × Leucovorin × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡